Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Advanced Endometrial Cancer Clinical Trial

Official title:
A Phase 2, Open-Label, Safety Lead-In With Long Term Safety Study of EG-007, Added to the Combination of Lenvatinib Plus Pembrolizumab

Status Not yet recruiting

Clinical Trial Summary

This is a Phase 2 trial Safety Lead-in trial conducted in 3 cohorts of patients. A safety lead-in study of the impact of adding the Repurposed Drugs a third agent will be conducted prior to opening enrollment into the compassionate use study. All patients enrolled in the safety lead-in study may continue long-term treatment under this protocol without interruption of dosing.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05106127
Study type	Interventional
Source	Evergreen Therapeutics, Inc.
Contact	Xin Du, Ph.D.
Phone	2404064016
Email	david.du@egpharm.com
Status	Not yet recruiting
Phase	Phase 2
Start date	March 2025
Completion date	October 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04574284` - A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer	Phase 2
Recruiting	`NCT05112991` - Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer	Phase 2
Completed	`NCT01289041` - BKM120 as Second-line Therapy for Advanced Endometrial Cancer	Phase 2
Not yet recruiting	`NCT05077215` - Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer	Phase 3
Recruiting	`NCT05481645` - Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.	Phase 2
Not yet recruiting	`NCT06046274` - GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer	Phase 2